Skip to main content
. Author manuscript; available in PMC: 2020 Sep 4.
Published in final edited form as: Exp Hematol. 2019 Sep 4;77:36–40.e2. doi: 10.1016/j.exphem.2019.08.007

Figure 1. K0706 inhibits native and mutant BCR-ABL1.

Figure 1.

(A) Structure of K0706. The boxed areas indicate sub-structure elements shared with ponatinib (blue box) and dasatinib (green box), which are shown for comparison. (B) Cellular IC50 values for K0706 in BCR-ABL1-positive and -negative cell lines. Note: Table S1: Comparison of K0706 to the BCR-ABL1 TKIs bosutinib, nilotinib, dasatinib, and ponatinib. (C) Immunoblot analysis of phosphorylation of BCR-ABL1 (pBCR-ABL1) in Ba/F3 cells expressing BCR-ABL1, BCR-ABL1L248V, BCR-ABL1Y253H, BCR-ABL1E255V, or BCR-ABLT315I following exposure to K0706.